CRISPR-Cas enzymes: The toolkit revolutionizing diagnostics.

Autor: Verosloff MS; Mammoth Biosciences, Inc., Brisbane, California, USA., Shapiro SJ; Mammoth Biosciences, Inc., Brisbane, California, USA., Hawkins EM; Mammoth Biosciences, Inc., Brisbane, California, USA., Alpay E; Mammoth Biosciences, Inc., Brisbane, California, USA., Verma D; Mammoth Biosciences, Inc., Brisbane, California, USA., Stanfield EG; Mammoth Biosciences, Inc., Brisbane, California, USA., Kreindler L; Mammoth Biosciences, Inc., Brisbane, California, USA., Jain S; Mammoth Biosciences, Inc., Brisbane, California, USA., McKay B; Mammoth Biosciences, Inc., Brisbane, California, USA., Hubbell SA; Mammoth Biosciences, Inc., Brisbane, California, USA., Hendriks CG; Mammoth Biosciences, Inc., Brisbane, California, USA., Blizard BA; Mammoth Biosciences, Inc., Brisbane, California, USA., Broughton JP; Mammoth Biosciences, Inc., Brisbane, California, USA., Chen JS; Mammoth Biosciences, Inc., Brisbane, California, USA.
Jazyk: angličtina
Zdroj: Biotechnology journal [Biotechnol J] 2022 Jul; Vol. 17 (7), pp. e2100304. Date of Electronic Publication: 2021 Sep 23.
DOI: 10.1002/biot.202100304
Abstrakt: The programmable nature of sequence-specific targeting by CRISPR-Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross-disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID-19 pandemic. We further discuss the advances and potential for CRISPR-based detection to have an impact across a continuum of diagnostic applications.
(© 2021 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: